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Autologous hematopoietic cell transplantation (AHCT) for plasma cell myeloma is performed less often in
people >70 years old than in people 70 years old. We analyzed 11,430 AHCT recipients for plasma cell
myeloma prospectively reported to the Center for International Blood and Marrow Transplant Research be-
tween 2008 and 2011, representing the majority of US AHCT activity during this period. Survival (OS) was
compared in 3 cohorts: ages 18 to 59 years (n ¼ 5818), 60 to 69 years (n ¼ 4666), and >70 years (n ¼ 946).
Median OS was not reached for any cohort. In multivariate analysis, increasing age was associated with
mortality (P ¼ .0006). Myeloma-speciﬁc mortality was similar among cohorts at 12%, indicating an age-
related effect on nonmyeloma mortality. Analyses were performed in a representative subgroup comparing
relapse rate, progression-free survival (PFS), and nonrelapse mortality (NRM). One-year NRM was 0% for age
>70 years and 2% for other ages (P ¼ not signiﬁcant). The three-year relapse rate was 56% in age 18 to 59
years, 61% in age 60 to 69 years, and 63% age >70 (P ¼ not signiﬁcant). Three-year PFS was similar at 42% in
age 18 to 59 years, 38% in age 60 to 69 years, and 33% in age >70 years (P ¼ not signiﬁcant). Postrelapse
survival was signiﬁcantly worse for the older cohort (P ¼ .03). Older subjects selected for AHCT derived
similar antimyeloma beneﬁt without worse NRM, relapse rate, or PFS.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION
Plasma cell myeloma is the most common indication for
autologous hematopoietic cell transplantation (AHCT);
however, a large number of eligible subjects are not offered a
transplantation because of advanced age [1-3]. Randomized
studies conﬁrm the beneﬁt of autologous transplantation in
subjects65 years of age, but these studies typically excluded
older subjects [4,5]. The median age at diagnosis of patients
with myeloma is 69 years and prospective transplantation
studies in these older subjects are limited or use lower doses
of conditioning [6]. Single-institution retrospective studies
suggest that older persons with myeloma may receive an
autologous transplantation with low risk of nonrelapse
mortality (NRM) [7-18]. It is also well established that the
recent dramatic improvements in survival have accrued
disproportionately to younger patients, with relativelyminor
improvement in survival of those above age 60 [19].
We analyzed the effects of age on outcomes in persons
with myeloma receiving upfront autologous transplantation.SUBJECTS AND METHODS
Data Source
The Center for International Blood and Marrow Transplant Research
(CIBMTR) is a voluntary group of more than 450 transplantation centers
worldwide that contribute data onallogeneic andautologous transplantations
to a statistical center at the Medical College of Wisconsin in Milwaukee orFigure 1. Adjusted probability of survival. (Lthe National Marrow Donor Program Coordinating Center in Minneapolis,
Minnesota. Participating centers are required to register all transplantations
done consecutively in a prospective fashion. Subjects are followed longitudi-
nally, with yearly data update. Computerized checks for errors, physicians’
review of submitted data, and on-site audits of participating centers are used
to ensure data quality and compliance. Studies conducted by the CIBMTR are
performed with a waiver of informed consent and in compliance with Health
Insurance Portability andAccountability Act regulations as determined by the
institutional review board and the privacy ofﬁcer of the Medical College of
Wisconsin. All CIBMTR centers contribute to the registration or transplant
essential data. Detailed data are collected on the comprehensive report form
(CRF) level on a subset of registered subjects and include detailed disease and
pretransplantation and post-transplantation clinical information. Statistical
methods (weighted randomization schema) are used to ensure that the CRF
subset are representative of the transplant essential data cohort.
Study Population
Outcomes of 11,430 AHCT recipients with plasma cell myeloma between
2008 and 2011 (n¼ 11,430) reported from 148 transplantation centers in the
United States and Canada were analyzed. During this period, the CIBMTR
collected 60% of AHCTactivity performed in the United States [20]. The study
population included only those receiving a single AHCT within 24months of
diagnosis and receiving high-dose melphalan alone as conditioning.
Statistical Plan
The objective of this study was to analyze the effect of age on survival,
NRM, relapse rates, and progression-free survival (PFS) after trans-
plantation. Survival after AHCT was compared and subject to multivariate
analyses in 3 age-dependent cohorts: ages 18 to 59 years (cohort 1, n ¼
5818), 60 to 69 years (cohort 2, n¼ 4666), and70 years (cohort 3, n¼ 946).eft) Shows OS and (Right) shows PFS.
Table 1
Characteristics of Subjects who Underwent First PBSC AHCT within Two Years of Diagnosis for Plasma Cell Myeloma in the United States and Canada, Registered
to CIBMTR between 2008 and 2011 (Transplant Essential Data)
Characteristics of Subjects Cohort 1 (ages 18-59 yr) Cohort 2 (ages 60-69 yr) Cohort 3 (70þ yr) P Value
No. of patients 5818 4666 946
Age at transplantation, median (range), yr 53 (18-59) 64 (60-69) 72 (70-89)
Age at transplantation, yr
18-49 yr 1728 (30) e e <.0001
50-59 yr 4090 (70) e e
60-64 yr e 2617 (56) e
65-69 yr e 2049 (44) e
70-74 yr e e 794 (83)
75-79 yr e e 146 (15)
80þ e e 6 (<1)
Male sex 3278 (56) 2689 (58) 608 (64) <.0001
Region
United States 5488 (94) 4424 (95) 938 (99) <.0001
Canada 330 (6) 242 (5) 8 (<1)
KPS before transplantation
>90 766 (13) 500 (11) 88 (9) <.0001
80-90 4213 (72) 3444 (74) 716 (76)
<80 515 (9) 515 (11) 106 (11)
Missing 324 (6) 207 (4) 8 (<1)
HCTCI score
0-1 3277 (56) 2373 (51) 454 (48) <.0001
2-3 1551 (27) 1295 (28) 307 (32)
4 725 (12) 795 (17) 117 (19)
Missing 265 (5) 203 (4) 8 (<1)
Serum creatinine  1.5 at diagnosis 164 (23) 121 (24) 17 (24)
Immunochemical subtype of plasma cell myeloma
IgG 3312 (57) 2690 (58) 535 (57) <.0001
IgA 1127 (19) 1028 (22) 234 (25)
Light chain 1170 (20) 807 (17) 152 (16)
Others (Ig M, D, or E) 82 (1) 45 (1) 11 (1)
Nonsecretory 127 (2) 96 (2) 14 (1)
Disease status at transplantation
CR 839 (14) 662 (14) 117 (12) .1209
VGPR 1628 (28) 1384 (30) 278 (29)
PR 2798 (48) 2186 (47) 462 (49)
SD 341 (6) 248 (5) 57 (6)
REL/PROG 180 (3) 170 (4) 31 (3)
Missing 32 (<1) 16 (<1) 1 (<1)
MEL 200 (100-220) 200 (100-220) 200 (100-200)
<140 140 (2) 132 (3) 44 (5) <.0001
140-180 336 (6) 552 (12) 354 (37)
180 4982 (86) 3715 (80) 480 (51)
Missing 330 (6) 267 (6) 68 (7)
Time from diagnosis to transplantation, median (range), mo 7 (<1-24) 8 (<1-24) 8 (<1-24)
<12 mo 4739 (81) 3632 (78) 745 (79) <.0001
12-18 mo 760 (13) 698 (15) 136 (14)
18-24 mo 319 (6) 336 (7) 65 (7)
Yr of transplantation
2008 1177 (20) 877 (19) 149 (16)
2009 1392 (24) 1077 (23) 195 (21)
2010 1566 (27) 1273 (27) 286 (30)
2011 1683 (29) 1439 (31) 316 (33)
VGPR indicates very good partial response; PR, partial response; SD, stable disease; REL, relapse; PROG, progression.
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subjects with CRF data after ensuring that survival was identical to the larger
sample (Supplemental Figure 1). NRM was deﬁned as mortality after AHCT
in the absence of disease relapse or progression. Cumulative incidence
probabilities for NRM were calculated accounting for relapse/progression as
a competing risk. Point-wise comparison and log-rank analysis were used to
analyze the NRM and survival of different groups.
Subject characteristics in study cohorts were compared using theMann-
Whitney-Wilcoxon test for continuous variables and chi-square test for
discrete variables. Survival probabilities (overall survival [OS] and PFS) were
calculated by using the Kaplan-Meier estimator with the variance estimated
by Greenwood’s formula. Multivariate analysis was performed using Cox
proportional hazard regression model to adjust for potentially confounding
effects of other risk factors. The variables considered in multivariate analysis
for survival included age, HCT-speciﬁc comorbidity index (HCTCI) [21,22],
Karnofsky performance score (KPS), time from diagnosis to transplantation,
year of transplantation, disease status at the time of transplantation, and the
dose of melphalan conditioning regimen (in mg/m2). The variablesconsidered in multivariate analyses for NRM, progression/relapse, and PFS
included age, gender, KPS, HCTCI, disease status at the time of trans-
plantation, melphalan dose (mg/m2), time from diagnosis to trans-
plantation, and the year of transplantation. Stepwise variable selection at a
.05 signiﬁcance level was used to identify signiﬁcant covariates. In the
model, the assumption of proportional hazards was tested for each variable
using a time-dependent covariate and graphical methods. All variables
considered in the multivariate analysis satisﬁed the proportionality
assumption. All computations were made using the statistical package SAS
version 9.1 (SAS Institute, Cary, NC).RESULTS
Subject Characteristics
Subject characteristics are summarized in Table 1, which
compares 3 cohorts: patients from 18 to 59 years old (cohort 1,
n¼ 5818), 60 to69years old (cohort 2, n¼ 4666), and70years
Table 2
Characteristics of Subjects with High-Level Data Reporting
Characteristics of Subjects Cohort 1 (18-59 yr) Cohort 2 (60-69 yr) Cohort 3 (70þ yr) P Value
No. of subjects 710 498 71
Age at transplantation, median (range), yr 53 (22-59) 64 (60-69) 71 (70-78)
Age at transplantation, yr
18-49 yr 222 (31) e <.0001
50-59 yr 488 (69) e e
60-64 yr e 303 (61) e
65-69 yr e 195 (39) e
70-74 yr e e 64 (90)
75-79 yr e e 7 (10)
Male sex 408 (57) 275 (55) 49 (69) .0878
Region
United States 693 (98) 484 (97) 70 (99) .7494
KPS before transplantation
80 394 (55) 248 (50) 35 (49) .3293
<80 281 (40) 219 (44) 31 (44)
Missing 35 (5) 31 (6) 5 (7)
HCTCI score
0-1 423 (60) 280 (56) 36 (51) .6178
2-3 195 (27) 138 (28) 23 (32)
3 79 (11) 69 (14) 11 (15)
Missing 13 (2) 11 (2) 1 (1)
Immunochemical subtype of plasma cell myeloma
IgG 410 (58) 297 (60) 40 (56) .7742
IgA 138 (19) 114 (23) 15 (21)
Light chain 135 (19) 71 (14) 14 (20)
Others (Ig D/M/E) 12 (2) 5 (1) 1 (1)
Nonsecretory 15 (2) 11 (2) 1 (1)
Serum creatinine at transplantation 1.5 70 (10) 71 (14) 13 (18) .0245
Lines of chemotherapy before transplantation
1 551 (78) 375 (75) 55 (77) .6394
2 159 (22) 123 (25) 16 (23)
Induction chemotherapy
Thalidomide þ bortezomib 58 (8) 43 (9) 6 (8) .1158
Lenalidomide þ bortezomib 160 (23) 79 (16) 12 (17)
Thalidomide-based 116 (16) 103 (21) 20 (28)
Lenalidomide-based 175 (25) 134 (27) 16 (23)
Bortezomib-based 161 (23) 116 (23) 14 (20)
Steroids/cytoxan 40 (6) 23 (5) 3 (4)
Disease status before AHCT
CR 114 (16) 85 (17) 12 (17) .8670
VGPR 199 (28) 143 (29) 22 (31)
PR 326 (46) 230 (46) 30 (42)
SD 56 (8) 32 (6) 4 (6)
REL/PROG 15 (2) 8 (2) 3 (4)
Sensitivity to chemotherapy before transplantation 639 (90) 458 (92) 64 (90) .4992
MEL, median (range), mg/m2 200 (116-214) 200 (137-220) 200 (108-200)
<140 mg/m2 5 (<1) 2 (3) 6 (8) <.0001
140-180 mg/m2 68 (10) 86 (17) 22 (31)
180- 200 mg/m2 631 (89) 406 (82) 43 (61)
Unknown 6 (<1) 4 (<1) 0 (0)
Cytogenetic before transplantation
Abnormal 311 (44) 220 (43) 33 (46) .2932
Normal 294 (41) 191 (38) 32 (45)
Untested/unknown 105 (15) 87 (17) 6 (8)
Time from diagnosis to transplantation, median (range), mo 7 (2-23) 8 (3-24) 8 (4-23)
<12 mo 605 (85) 411 (83) 61 (86) .5835
12-18 mo 77 (11) 66 (13) 6 (8)
19-24 mo 28 (4) 21 (4) 4 (6)
Type of transplantation
Single 632 (89) 454 (91) 70 (99) .0249
Tandem 78 (11) 44 (9) 1 (1)
Year of transplantation
2008 364 (51) 252 (51) 35 (49) .0068
2009 92 (13) 98 (20) 16 (23)
2010 102 (14) 53 (11) 12 (17)
2011 152 (21) 95 (19) 8 (11)
In-hospital days, median (range) 14 (0-71) 14 (0-60) 14 (0-42) .0012
Evaluable 597 (84) 442 (89) 64 (90)
Median follow-up of survivors, mo 35 (3-61) 37 (3-60) 36 (5-52)
Follow-up completeness index: at 1 year (99%), at 3 years (90%), and at 5 years (82%).
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1, 2, and 3 was 53, 64, and 72 years, respectively. Subjects in
cohort 3weremore likely to bemale, have their transplantationin the United States, have a lower Karnofsky score (KPS<90), a
worse comorbidity score (HCTCI>2), and have IgAmyeloma as
compared with those in cohorts 1 and 2. Older subjects in
Table 3
Univariate Results
Outcome At Risk, n Cohort 1 (18-59 yr) Cohort 2 (60-69 yr) Cohort 3 (70þ yr) P Value Cohort Comparison
Prob. % (95% CI) At Risk, n Prob. % (95% CI) At Risk, n Prob. % (95% CI) 1 versus 2 1 versus 3 2 versus 3
OS (n ¼ 11430)
At 1 yr 4430 94 (93-94) 3511 94 (93-94) 693 93 (91-94) .7490 .2123 .2874
At 2 yr 2505 86 (84-87) 1927 85 (83-86) 362 83 (80-85) .3003 .0737 .2272
At 3 yr 1168 78 (76-79) 904 75 (73-77) 133 72 (67-76) .0136 .0071 .1603
PFS (n ¼ 1279)
At 1 yr 492 77 (74-80) 340 77 (73-81) 52 80 (69-88) .8655 .5626 .5160
At 2 yr 267 56 (52-60) 198 57 (52-62) 25 50 (37-62) .7581 .3805 .3173
At 3 yr 136 42 (37-46) 101 38 (33-43) 12 33 (21-46) .2829 .2178 .4934
NRM (n ¼ 1279)
At 1 yr 492 2 (1-3) 340 2 (1-3) 52 0 .6264 .0003 .0048
At 2 yr 267 3 (2-5) 198 2 (1-3) 25 0 .1980 .0001 .0027
At 3 yr 136 3 (2-5) 101 2 (1-4) 12 6 (1-16) .3898 .4663 .3406
Progression (n ¼
1279)
At 1 yr 492 21 (18-24) 340 21 (18-25) 52 20 (11-30) .7525 .8481 .7359
At 2 yr 267 41 (37-45) 198 42 (37-46) 25 50 (37-62) .9546 .2075 .2264
At 3 yr 136 56 (51-60) 101 61 (55-66) 12 63 (48-74) .1827 .3570 .7900
Prob indicates probability.
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within the ﬁrst year of diagnosis and more likely to have
melphalan dose (MEL) reduction (MEL <180 mg/m2 in 42%).
Table 2 summarizes data in subset of subjects (n ¼ 1279)
analyzed for relapse and NRM, speciﬁcally. Survival curves
for this subset were identical to those of the larger set
(P ¼ .41, Supplemental Figure 1). There were 710 subjects in
cohort 1, 498 in cohort 2, and 71 in cohort 3 (Table 2). Age
distribution in the subset was similar to the total cohort of
11,430 subjects. Gender, KPS, HCTCI, immunochemical sub-
type, and time from diagnosis to AHCT showed similar dis-
tribution trends but did not reach statistical signiﬁcance,
primarily because of smaller cohort size. Higher interna-
tional staging system stage, serum creatinine at diagnosis,
and increased frequency of MEL reduction was noted in
subjects 70 years of age. The median time in the hospital
was 14 days for all cohorts. Median follow-up of survivors
was 3 years.OS (n ¼ 11430)
Median OS is not yet reached for any cohort. Survival data
at 1, 2, and 3 years are summarized in Table 3 and Figure 1. In
multivariate analysis, increasing age was associated with
worse survival (P ¼ .0006) (Table 4). Hazard ratios for death
were 1.12 (95% conﬁdence interval [CI], 1.02 to 1.24) for
cohort 1 versus cohort 2, 1.35 (95% CI, 1.15 to 1.59) for cohort
1 versus cohort 3, and 1.2 (95% CI, 1.02 to 1.42) for cohort 2
versus cohort 3. The primary cause of death was myeloma in
all 3 cohorts, with a similar myeloma-speciﬁc mortality rate
(Table 5). In multivariate analysis, signiﬁcant predictors of
worse survival were higher HCTCI score, lower KPS, longer
interval from diagnosis to transplantation, and inferior dis-
ease status (not in complete remission [CR]) at
transplantation.Relapse (n ¼ 1279)
The 3-year rate of relapse was 56% (95% CI, 51% to 60%),
61% (95% CI, 55% to 66%), and 63% (95% CI, 48% to 74%) in
cohorts 1, 2, and 3, respectively, which was not statistically
signiﬁcant (Table 3, Figure 2). On multivariate analysis, a
lower KPS (<80), longer interval from diagnosis to AHCT
(>12 months), and inferior disease status before AHCT (notin CR) were predictive factors for relapse. Increasing age was
not associated with greater incidence of relapse.
PFS (n ¼ 1279)
The 3-year PFS in cohorts 1, 2, and 3 was similar at 42%
(95% CI, 37% to 46%), 38% (95% CI, 33% to 43%), and 33% (95%
CI, 21% to 46%), respectively, which was not statistically sig-
niﬁcant (Figure 1). Age was not a signiﬁcant risk factor for
PFS in multivariate analysis; however, KPS, longer interval
from diagnosis to transplantation, and more advanced dis-
ease (not in CR) at transplantationwere signiﬁcant predictors
of treatment failure (and worse PFS).
NRM (n ¼ 1279)
One-year NRM was 0% for cohort 3 and 2% (95% CI, 1% to
3%) for cohorts 1 and 2, respectively (Figure 2). Age was not
signiﬁcantly associated with NRM in multivariate analysis
but KPS <80% was predictive in multivariate analysis.
Postrelapse Survival
Survival after myeloma relapse was signiﬁcantly worse
for cohort 3 (P ¼ .03, Figure 3). The 2-year postrelapse sur-
vivals were 63% (95% CI, 56% to 69%), 50% (95% CI, 42% to
57%), and 54% (95% CI, 32% to 71%) for cohorts 1, 2, and 3,
respectively.
Causes of Death
The primary cause of death was myeloma in all 3 cohorts
(Table 5). Incidence of second malignancy was similar and
low at<1%. A higher proportion of deaths in the older cohort
were attributed to vascular and unknown causes.
Outcomes in Those >75 Years Old
There were 146 patients 75 to 79 years old and 8 who
were  80 years old. The use of reduced MEL (<180 mg/m2)
was 57% among those 75 to 79 years old and 67% in those
80 years old. Two-year survival in the 75 to 79eyear-old
cohort and 80-years-old cohort was 91% (83% to 95%) and
100%, respectively.
DISCUSSION
Our data indicate that freedom from progression of
myeloma is similar regardless of age in persons who receive
Table 4
Multivariate Analyses
Risk Factors Hazard Ratio (95% CI) P Value
For mortality:
Age group (main effect) Overall test .0006*
Reference group : 18-59 yr 1 NA
60-69 versus 18-59 yr 1.123 (1.018-1.239) .0204*
70þ versus 18-59 yr 1.353 (1.150-1.593) .0003*
70þ versus 60-69 yr 1.205 (1.022-1.420) .0261*
HCTCI Overall test <.0001*
 2 versus <2 1.279 (1.163-1.407) <.0001*
KPS Overall test <.0001*
80-90 versus 100 1.242 (1.058-1.407) .0082*
<80 versus 100 1.640 (1.344-2.002) <.0001*
Time from diagnosis to transplantation
12-24 versus 0-12 mo 1.321 (1.188-1.469) <.0001*
Disease status at transplantation Overall test <.0001*
VGPR/PR versus CR 1.313 (1.127-1.530) .0005*
SD versus CR 1.693 (1.353-2.119) <.0001*
REL/PROG versus CR 3.301 (2.647-4.116) <.0001*
For treatment failure/PFS:
Age group (main effect) Overall test .7014
60-69 versus 18-59 yr 1.046 (.892-1.226) .5832
70þ versus 18-59 yr 1.131 (.816-1.567) .4598
70þ versus 60-69 yr 1.082 (.776-1.507) .6433
KPS Overall test .0029*
80-90 versus 100 1.069 (.817-1.398) .6279
<80 versus 100 1.594 (1.128-2.253) .0082*
Time from diagnosis to transplantation
12-24 versus 0-12 mo 1.294 (1.066-1.571) .0092*
Disease status at transplantation Overall test <.0001*
VGPR/PR versus CR 1.327 (1.062-1.658) .0129*
SD versus CR 1.963 (1.423-2.708) <.0001*
REL/PROG versus CR 3.076 (1.882-5.028) <.0001*
For NRM:
Age group (main effect) Overall test .9734
60-69 versus 18-59 yr .921 (.450-1.884) .8214
70þ versus 18-59 yr 1.006 (.232-4.365) .9941
70þ versus 60-69 yr 1.092 (.245-4.866) .9082
KPS Overall test
80-90 versus 100 2.890 (.389-21.485) .2998
<80 versus 100 9.554 (1.170-78.039) .0352*
Time from diagnosis to transplantation
12-24 versus 0-12 mo 2.158 (.997- 4.668) .0508
For progression:
Age group (main effect) Overall test .6811
60-69 versus 18-59 yr 1.052 (.893-1.238) .5465
70þ versus 18-59 yr 1.136 (.813-1.587) .4548
70þ versus 60-69 yr 1.080 (.769-1.518) .6561
KPS Overall test .0209*
80-90 versus 100 1.039 (.792-1.363) .7847
<80 versus 100 1.456 (1.020-2.079) .0385*
Time from diagnosis to transplantation
12-24 versus 0-12 mo 1.259 (1.031-1.539) .0241*
Disease status at transplantation Overall test <.0001*
VGPR/PR versus CR 1.299 (1.036-1.630) .0237*
SD versus CR 1.935 (1.939-2.688) <.0001*
REL/PROG versus CR 3.074 (1.858-5.085) <.0001*
* Signiﬁcant at level of .05.
Table 5
Causes of Death
Characteristics of Patients Cohort 1
(18-59 yr)
Cohort 2
(60-69 yr)
Cohort 3
(70þ yr)
No. of patients 5818 4666 946
No. of deaths 843 770 176
Myeloma 655 (11) 552 (12) 118 (12)
Infection 23 (<1) 18 (<1) 3 (<1)
Pulmonary 3 (<1) 3 (<1) 1 (<1)
Organ failure 14 (<1) 20 (<1) 6 (<1)
Secondary malignancy 11 (<1) 16 (<1) 5 (<1)
Hemorrhage 1 (<1) 0 (0) 0 (0)
Vascular/thrombotic/other 136 (3) 161 (3) 43 (5)
Data presented are n (%) unless otherwise indicated.
Figure 2. Relapse and NRM.
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in older persons. Interestingly, the increased mortality was
not correlated with NRM or early progression but rather with
worse postrelapse survival. The cause of death in these older
subjects was mainly myeloma (as it was in younger cohorts)
and not from transplantation-related causes, as might be
speculated. Lack of clinical studies speciﬁcally applicable to
this subject population may contribute to limited options
after relapse and postrelapse survival [23]. The role of post-
AHCT maintenance therapy was not analyzed in this study
and, as such, we are unable to determine if differential use of
maintenance therapy contributed to the results.
The survival analysis presented involves >11,000 subjects
and represents approximately prospectively collected data atthe time of transplantation, and longitudinally thereafter, in
60% of all AHCT for multiple myeloma (MM) in the United
States. The characteristics of the elderly population receiving
AHCT and the practice of AHCT are, thus, indicative of actual
practice. In the older cohort, we observed signiﬁcant MEL
reductions (MEL <180 mg/m2 in 42%), worse HCTCI and KPS,
and approximately 40% in > very good partial response
(VGPR) disease state before AHCT. Multivariate analysis
revealed that the risk factors for earlier relapse and shorter
PFS included a lower KPS, longer time from diagnosis to
transplantation, and a less than very good partial response
before transplantation. NRM was 0% in subjects >70 years
old, which indicates that careful subject selection and dose
adjustment of melphalan were highly successful at control-
ling treatment toxicity without compromising beneﬁt.
The perception of advanced age being an indicator of
inferior outcomes after an autologous transplantation is a
barrier to using high-dose melphalan as a therapeutic mo-
dality. Although autologous transplantation is now being
offered more often to older patients, there still remains a
large population of eligible patients who can beneﬁt from
this treatment modality [24]. The inclusion of older patients
eligible for an autologous transplantation has been, in part,
due to the improvement in supportive care and improved
understanding of patient selection, as well as several studies
showing that biologic ﬁtness, rather than chronological age,
is crucial in patient selection for transplantation in general
[25,26]. The alternatives to autologous transplantation for
older subjects include the continuation of the induction
antimyeloma regimen or oral melphalan and prednisone
(MP)ebased induction regimens. Until recently, MP in
combination with thalidomide, lenalidomide, or bortezomib
was believed to be the optimal treatment strategy for
Figure 3. Postrelapse OS.
M. Sharma et al. / Biol Blood Marrow Transplant 20 (2014) 1796e18031802transplantation-ineligible subjects. In a recent study,
ongoing lenalidomide plus dexamethasone was shown to be
superior to oral melphalan, prednisone, and thalidomide in a
phase III randomized study [27].
MP has been studied in combination with thalidomide
(MPT) [28-33], lenalidomide [34], and bortezomib [35-38] in
randomized, phase III trials in Europe. The NRM using these
regimens is 5% to 7% in patients selected for clinical trials,
and OS has been shown to be higher in patients receiving
either MPT or MP with bortezomib, compared with MP.
Facon et al. compared the outcomes in older subjects
randomized to either MP, MPT, or to an autologous
transplantation using lower intensity conditioning with
melphalan 100 mg/m2 [30]. The incidence of death in the
ﬁrst 3 months of therapy in theMP, MPT, and transplantation
group was 7%, 2%, and 9%, respectively. The MPT arm was
associated with a longer PFS and OS, compared with trans-
plantation or MP, which had similar outcomes.
Palumbo et al. compared MP versus 2 courses of
melphalan 100 mg/m2 followed by stem cell transplantation
and were able to show an improvement in event-free sur-
vival and OS in patients receiving stem cell transplantation
[39]. Whether a single melphalan 140 mg/m2 is equivalent to
a single melphalan 200 mg/m2 is currently unknown. In our
study, melphalan dose reduction did not impact myeloma-
related outcomes, although the majority of >70-year-old
patients still received melphalan 200 mg/m2. However, it
seems that the optimal manner in which to administer
melphalan is at higher doses with autologous stem cell
support, rather than as a part of MP-based regimens, as NRM
is lower in the transplantation strategy in the modern era.
Notably, our subjects underwent transplantation more
recently compared with the studies mentioned above, and
97% received a novel agent (lenalidomide or bortezomib)e
based induction regimen.
Inconclusion, advancedsubject agewasnotassociatedwith
a worse NRM, relapse rate, or PFS after AHCT for MM. Post-
relapse survival and OS of older subjects were inferior
comparedwithyounger subjects,which is likelymultifactorial.
Subjects with MM and an adequate performance status or
acceptable HCTCI scores should not be considered for AHCTon
the basis of age alone. Strategies offered to younger patients,
such aspost-AHCTmaintenance, aggressive therapyat relapse,
and clinical trial enrollment, may improve overall and post-
relapse outcomes further for older persons with myeloma.
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